Affiliation:
1. Division of Neuropharmacology and Neurologic Diseases, Yerkes National Primate Research Center; Atlanta, GA, United States
Abstract
The plasminogen activation (PA) system was originally thought to exclusively promote the
degradation of fibrin by catalyzing the conversion of plasminogen into plasmin via two serine proteinases:
tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA). However,
experimental evidence accumulated over the last 30 years indicates that tPA and uPA are also
found in the central nervous system (CNS), where they have a plethora of functions that not always
require plasmin generation or fibrin degradation. For example, plasminogen-dependent and -
independent effects of tPA and uPA play a central role in the pathophysiological events that underlie
one of the leading causes of mortality and disability in the world: cerebral ischemia. Indeed, recent
work indicates that while the rapid release of tPA from the presynaptic compartment following the onset
of cerebral ischemia protects the synapse from the deleterious effects of the ischemic injury, the
secretion of uPA and its binding to its receptor (uPAR) during the recovery phase promotes the repair
of synapses that have been lost to the acute ischemic insult. This restorative role of uPA has high
translational significance because to this date there is no effective approach to induce neurorepair in
the ischemic brain. Here we will discuss recent evidence that bridges the gap between basic research
in the field of the PA system and the bedside of ischemic stroke patients, indicating that uPA and
uPAR are potential targets for the development of therapeutic strategies to promote neurological recovery
among ischemic stroke survivors.
Funder
National Institutes of Health
Publisher
Bentham Science Publishers Ltd.
Subject
Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Medicine
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献